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Objective. Plasmacytoid dendritic cells (PDCs)
are a critical source of type I interferons (IFNs) that
can contribute to the onset and maintenance of autoim-
munity. Molecular mechanisms leading to PDC dysreg-
ulation and a persistent type I IFN signature are largely
unexplored, especially in patients with systemic sclerosis
(SSc), a disease in which PDCs infiltrate fibrotic skin
lesions and produce higher levels of IFNa than those in
healthy controls. This study was undertaken to investi-
gate potential microRNA (miRNA)–mediated epigenetic
mechanisms underlying PDC dysregulation and type I
IFN production in SSc.
Methods. We performed miRNA expression pro-
filing and validation in highly purified PDCs obtained
from the peripheral blood of 3 independent cohorts of
healthy controls and SSc patients. Possible functions of
miRNA-618 (miR-618) on PDC biology were identified
by overexpression in healthy PDCs.
Results. Expression of miR-618 was up-regulated
in PDCs from SSc patients, including those with early
disease who did not present with skin fibrosis. IFN reg-
ulatory factor 8, a crucial transcription factor for PDC
development and activation, was identified as a target
of miR-618. Overexpression of miR-618 reduced the
development of PDCs from CD341 cells in vitro and
enhanced their ability to secrete IFNa, mimicking the
PDC phenotype observed in SSc patients.
Conclusion. Up-regulation of miR-618 sup-
presses the development of PDCs and increases their
ability to secrete IFNa, potentially contributing to the
type I IFN signature observed in SSc patients. Consid-
ering the importance of PDCs in the pathogenesis of
SSc and other diseases characterized by a type I IFN
signature, miR-618 potentially represents an important
epigenetic target to regulate immune system homeosta-
sis in these conditions.
Plasmacytoid dendritic cells (PDCs) are a unique
subset of DCs that specialize in the secretion of type I
interferons (IFNs) upon recognition of microbial single-
Supported by Reumafonds (project 13-2-304). Dr. Rossato’s
work was supported by the European Commission (IEF Marie Curie
Actions fellowship 622811; project MicroSCAP). Dr. Affandi’s work
was supported by Reumafonds (grant NR-10-1-301) and the Nether-
lands Organization for Scientific Research (NWO; Mosaic grant
017.008.014). Dr. Broen’s work was supported by a personal Veni
grant from the NWO (project 91614041). Dr. Radstake’s work was
supported the European Research Council (starting grant ERC-2011-
StG; project Circumvent).
1Marzia Rossato, PhD, Alsya J. Affandi, PhD, Catharina G. K.
Wichers, BASc, Marta Cossu, MD, Jasper C. A. Broen, MD, PhD,
Frederique M. Moret, PhD, Eleni Chouri, MSc, Lenny van Bon, MD,
PhD, Femke Wolters, MD, Wioleta Marut, PhD, Maarten van der Kroef,
MSc, Sandra Silva-Cardoso, MSc, Cornelis P. J. Bekker, PhD, Jacob M.
van Laar, MD, PhD, Joel A. G. van Roon, PhD, Kris A. Reedquist, PhD,
Timothy R. D. J. Radstake, MD, PhD: University Medical Center Utrecht,
Utrecht, The Netherlands; 2Soley Thordardottir, MSc, Harry Dolstra,
PhD: Radboud University Medical Center, Nijmegen, The Nether-
lands; 3Lara Bossini-Castillo, PhD: Consejo Superior de Investigaciones
Cientıficas, Granada, Spain, and Wellcome Trust Sanger Institute,
Cambridge, UK; 4Javier Martin, MD, PhD: Consejo Superior de
Investigaciones Cientıficas, Granada, Spain; 5Lorenzo Beretta, MD,
PhD: Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
di Milano, Milan, Italy.
Address correspondence to Marzia Rossato, PhD, University
Medical Centre Utrecht, Heidelberglaan 100, Laboratory of Transla-
tional Immunology, Utrecht 3508 AB, The Netherlands. E-mail: marzia.
rossato1@gmail.com.
Submitted for publication August 31, 2016; accepted in
revised form May 23, 2017.
1891
stranded RNA or double-stranded DNA by Toll-like
receptor 7 (TLR-7) and TLR-9, respectively (1). Several
observations suggest that PDCs may be the major
source of IFNa in autoimmune conditions characterized
by increased expression of IFN-responsive genes, sub-
stantially contributing to their pathogenesis (2–4). IFNa
may promote peripheral tolerance breakdown through
the activation of immature myeloid dendritic cells and
autoreactive T and B cells, thus leading to autoantibody
production (5). Supporting this concept, the depletion
of PDCs in murine models of systemic lupus erythema-
tosus (SLE) reduces the activation and expansion of
autoreactive immune cells, limits autoantibody produc-
tion and organ involvement, and leads to decreased
transcription of IFN-dependent genes (6–8).
A type I IFN signature has been consistently
observed in patients with systemic sclerosis (SSc), a sys-
temic autoimmune disorder characterized by fibrosis of
the skin and internal organs, accompanied by vascular
and immune dysfunction (9). Aberrant expression of
IFN-responsive genes was detected both in the affected
skin and in peripheral leukocytes from SSc patients,
correlating with disease activity (10). Increased serum
levels of IFNa and IFN-induced cytokines positively
associate with severe disease manifestations, such as
pulmonary arterial hypertension (PAH), lung fibrosis,
and digital loss (11). Anti–topoisomerase I antibody–
containing SSc sera induce IFNa production from
healthy donor leukocytes, particularly from PDCs
(11,12). We recently demonstrated that PDCs from SSc
patients can infiltrate fibrotic skin and produce high lev-
els of CXCL4, a chemokine associated with progressive
fibrosis and PAH and proposed as an SSc biomarker
(13). Increased plasma levels of CXCL4 could also be
observed in subjects with prefibrotic disease, who also
present with the typical type I IFN signature in circulat-
ing monocytes (13,14). Despite these findings suggesting
a relevant role of PDCs in SSc pathogenesis, the molec-
ular mechanisms leading to persistent PDC dysregula-
tion and the type I IFN response in SSc have not yet
been explored.
Epigenetic alterations, including DNA methyla-
tion, chromatin marks, and microRNAs (miRNAs),
could be critical to the breakdown of tolerance and the
development of systemic autoimmune diseases (15).
MicroRNAs are single-stranded short noncoding RNAs
of 18–23 nucleotides that are able to inhibit gene expres-
sion posttranscriptionally. The binding of miRNAs to
the 30-untranslated region (30-UTR) of protein-coding
messenger RNAs (mRNAs) leads to the inhibition of
target translation or, to a lesser extent, mRNA degrada-
tion. Even if the inhibitory effect of a single miRNA is
generally mild (16,17), each miRNA can regulate multi-
ple distinct transcripts and have multiple binding
sites on a single mRNA transcript, thus amplifying its
impact (18). MicroRNA-mediated regulation has been
shown to be crucial in the maintenance of normal
homeostatic processes, and the expression of miRNAs
is altered in multiple autoimmune conditions, including
SSc. The miRNAs miR-21 and miR-29a were reproduc-
ibly reported to be dysregulated in SSc skin and fibro-
blasts, where they act as profibrotic and antifibrotic
factors, respectively (19). However, so far no study has
addressed the potential involvement of miRNAs in the
aberrant behavior of the immune system in SSc patients.
In this study we investigated the potential role of
miRNAs in the altered maturation and function of
PDCs in SSc patients, and identified miR-618 as a possi-
ble important contributor to this process.
PATIENTS AND METHODS
Patients. Peripheral blood samples from patients and
sex- and age-matched healthy donors were obtained from the
Boston University School of Medicine (Boston, MA; discovery
cohort), University Medical Center Utrecht and Radboud
University Nijmegen (fibrotic cohort), and IRCCS Policlinico
of Milan (nonfibrotic cohort). All patients and healthy donors
signed an informed consent form approved by the local institu-
tional review boards prior to participation in the study, as
previously described (13). Samples and clinical information
were made anonymous immediately after collection. The
demographic and clinical characteristics of the patients
included in the study are shown in Table 1. SSc patients ful-
filled the American College of Rheumatology/European
League Against Rheumatism 2013 classification criteria (20)
and were categorized according to the extent of skin fibrosis as
having limited cutaneous SSc (lcSSc) or diffuse cutaneous SSc
(dcSSc) (21). Patients with dcSSc with a disease duration of
#24 months were classified as having early dcSSc, while those
with a longer disease duration were classified as having late
dcSSc (13). Patients who fulfilled the classification criteria but
did not present with skin fibrosis are referred to as patients
with noncutaneous SSc. Finally, we also included patients with
Raynaud’s phenomenon and positivity for SSc-specific auto-
antibodies and/or typical nailfold capillaroscopy abnormalities,
who are referred to as patients with “early SSc” in ref. 22 or as
patients with “undifferentiated connective tissue disease at
risk for SSc” in ref. 23.
The fibrotic cohort comprised healthy controls, lcSSc
patients, and dcSSc patients, while the nonfibrotic cohort com-
prised healthy controls and patients with noncutaneous SSc
and those with early SSc, who did not have skin involvement.
The presence of interstitial lung disease (ILD) was defined as
typical involvement of the lung parenchyma .5% on high-
resolution computed tomography accompanied by reduced
forced vital capacity or diffusing capacity for carbon monoxide
,80% of predicted values. PAH was confirmed by catheteriza-
tion of the right side of the heart.
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Cell isolation and culture. PDCs and monocytes
were isolated by positive selection from peripheral blood
mononuclear cells using immunomagnetic labeling (blood
dendritic cell antigen 4 [BDCA-4]/neuropilin 1 and CD14
MicroBead kits, respectively) on an AutoMACS Pro column
(Miltenyi Biotec). The purity of isolated PDCs (.90%) was
assessed by fluorescence-activated cell sorting (FACS) after
staining with anti–BDCA-4 and CD123 (data available upon
request from the corresponding author). PDCs from selected
healthy controls were cultured in RPMI 1640 GlutaMax
(Gibco) containing 10% heat-inactivated fetal bovine serum
(FBS; BioWest), penicillin/streptomycin (Gibco), and 10 ng/
ml interleukin-3 (IL-3) (ImmunoTools).
The CAL-1 human PDC line, established from a blastic
natural killer cell lymphoma (24), was grown in complete
RPMI 1640 medium (Gibco) supplemented with 2 mM L-glu-
tamine, 1 mM sodium pyruvate, 10 mM HEPES, 13 minimum
essential medium, nonessential amino acids (Gibco), and 10%
FBS. Cells were cultured for fewer than 3 weeks at a concen-
tration of ,106 cells/ml, by passaging every 2 days. HEK 293
cells were cultured in Dulbecco’s modified Eagle’s medium
(4.5 gm/liter glucose) with GlutaMax (Gibco), supplemented
with 10% FBS and 1% penicillin/streptomycin.
CAL-1 and PDC transfection. CAL-1 cells (n5
200,000) or PDCs (n5 100,000) isolated from healthy controls
were transfected using Lipofectamine Plus (Invitrogen) for 4
hours with 500 nM miR-618 mimic or scrambled miRNA control
(Ambion); 100 nM Stealth small interfering RNA against IFN
regulatory factor 8 (IRF-8) mRNA (assay IDs HSS105169,
HSS105170, and HSS105171) or a scrambled control (Life Tech-
nologies); or 100 nM miRCURY LNA Power microRNA miR-
618 inhibitor (anti–miR-618) or control A (anti–scrambled
miRNA) (Exiqon). The miRCURY LNA Power microRNA
inhibitors block miRNA activity by forming stable complexes with
them and do not induce miRNA degradation (https://www.exiqon.
com/ls/Documents/Scientific/miRNA-inhibitor-manual.pdf). Cells
were allowed to recover overnight in complete medium, and the
next day were left untreated or stimulated with 1 mM
unmethylated type C CpG-containing oligodeoxyribonucleotide
(CpG ODN) (InvivoGen) for 24 hours. Supernatants were
harvested for Luminex-based immunoassay, and cells were lysed
for RNA extraction or processed for flow cytometric analysis.
IRF-8 intracellular staining. After staining with
fixable viability dye e450 (eBioscience) and fluorochrome-
conjugated antibodies against CD303 (Miltenyi Biotec) and
CD123 (BioLegend), PDCs or CAL-1 cells were fixed and
permeabilized using FoxP3/Transcription Factor Staining
Buffer Set (eBioscience). Cells were labeled with anti–IRF-8 anti-
body (eBioscience) or mouse IgG isotype control (eBioscience),
and data were acquired on an LSRFortessa (BD Biosciences)
and analyzed using FlowJo software (Tree Star).
Generation of DCs from CD341 hematopoietic stem
cells. CD341 stem cells (89–97% pure) were isolated from
the granulocyte colony-stimulating factor–mobilized periph-
eral blood of healthy donors using anti-CD34 immuno-
magnetic CliniMACS beads (Miltenyi Biotec). Generation of
CD34-derived DCs was performed as previously described
with minor adjustments (25). Briefly, CD341 cells were cul-
tured in Cellgro DC medium (CellGenix) supplemented with
2% human serum (PAA Laboratories), 1 mM StemRegenin 1
(Cellagen Technology), 50 mg/ml vitamin C (Centrafarm), and
100 ng/ml of the following cytokines: thrombopoietin, stem
cell factor, and Flt-3L (ImmunoTools). Medium was refreshed
every 2–3 days and generation of DCs was evaluated by surface
staining with antibodies against BDCA-4 (BioLegend), CD123
(BD Biosciences), HLA–DR (Beckman Coulter), and CD14
(Beckman Coulter). Cells were acquired on a Gallios flow
cytometer (Beckman Coulter) and analyzed with FlowJo soft-
ware (Tree Star).
Viral transduction of CD34-derived cell culture.
HEK 293T cells were transfected with lentiviral packaging
plasmids (pMD2G and psPAX2) and pEZX-MR03-GFP
encoding for pre–miR-618 or a pre–scrambled miRNA (Gene-
Copoeia) using Lipofectamine (Invitrogen). Medium was
changed 24 hours later. Lentiviral particles were collected 48
hours after transfection and concentrated by ultracentrifuga-
tion. CD34-derived cells (n5 500,000) in CD341 DC culture
medium were transduced on day 3 in 35-mm–diameter petri
dishes (Corning) precoated with 1.25 mg/cm2 RetroNectin
(Takara), by adding 1 ml of viral particles. Seventy-two hours
after transduction, transduced cells were isolated by FACS
Table 1. Demographic and clinical characteristics of the controls and SSc patients*
No.
Age,
years
Female,
no.
(%)
Disease
duration,
years
ANA
positive,
no. (%)
ACA
positive,
no. (%)
Antitopo
positive,
no. (%) MRSS
FVC, %
predicted
DLCO, %
predicted
Discovery cohort
Healthy controls 7 46.5 (35.3–48) 6 (85.7) NA NA NA NA NA NA NA
Late dcSSc 7 47 (37.5–59.5) 6 (85.7) 4 (3.5–7.5) 6 (85.7) 1 (14.3) 5 (71.4) 18.5 (8.8–23.8) 56 (45.8–70) 47 (40–48.8)
Early dcSSc 5 52.5 (46.3–62.5) 5 (100) 2 (1.25–2) 5 (100) 0 (0) 4 (80) 23 (18–46) 90 (55–92) 56.5 (44.3–76.3)
Fibrotic cohort
Healthy controls 23 51.5 (42–59.8) 17 (73.9) NA NA NA NA NA NA NA
lcSSc 25 54 (49–61) 18 (72) 5 (2–14) 23 (92) 12 (48) 4 (16) 4 (1.75–7.5) 105 (88–116) 66 (39.8–82.3)
dcSSc 10 55 (43.8–66) 4 (40) 2 (1.5–4.5) 10 (100) 0 (0) 7 (70) 13 (8.5–21.5) 59 (51–69.3) 42 (29.8–58)
Nonfibrotic cohort
Healthy controls 11 35 (30–47) 10 (90.9) NA NA NA NA NA NA NA
Early SSc 23 46 (40.1–66.5) 21 (91.3) NA 20 (86.9) 12 (52.2) 3 (13.0) 0 108 (101–121) 82 (68–100)
Noncutaneous SSc 12 56 (49.2–66.4) 12 (100) 1 (1–5.5) 12 (100) 11 (91.7) 0 (0) 0 121 (93.5–118.5) 80 (69–98)
* Except where indicated otherwise, values are the median (interquartile range). SSc5 systemic sclerosis; ANA5 antinuclear antibody;
ACA5 anticentromere antibody; antitopo5 antitopoisomerase antibody; MRSS5modified Rodnan skin thickness score; FVC5 forced vital
capacity; DLCO 5 diffusing capacity for carbon monoxide; NA5 not applicable; dcSSc5diffuse cutaneous SSc; lcSSc5 limited cutaneous SSc.
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using a FACSAria sorter (BD Biosciences) on the basis of
GFP expression and cultured for an additional 7 days in
CD341 DC culture medium.
RNA extraction. Total RNA, including the small
RNA fraction, was isolated from cell lysates using an AllPrep
Universal kit (Qiagen), according to the manufacturer’s
instructions. RNA from whole blood was obtained using a
PAXgene Blood RNA system (Qiagen) following the manu-
facturer’s recommendations. RNA was quantified with a Qubit
RNA kit (Life Technologies), and RNA integrity was evalu-
ated using an Agilent Bioanalyzer.
Profiling of miRNA. Mature miRNAs were amplified
from 100 ng of total RNA with the Illumina human miRNA
profiling panel kit version 1, which contains primers for 470
annotated human miRNAs. The resulting amplicons were
hybridized to a 96-sample universal probe capture array, and
fluorescent signals were detected by confocal laser scanning.
All steps were performed according to the Illumina instruction
manual. Intensity data were processed using Beadstudio soft-
ware. Data filtering and normalization were performed using
GenePattern (Broad Institute). Differentially expressed
miRNAs were identified by applying comparative marker
selection analysis and 10,000 permutations (random seed:
779948241) to achieve correction for multiple testing. The
miRNA profiling data have been submitted to the Gene
Expression Omnibus with accession no. GSE100867.
Analysis of miRNA and gene expression. Expression
analysis of individual miRNAs was performed using TaqMan
miRNA Human Assays (Life Technologies), using 10 ng of
total RNA. Complementary DNA specific to miRNA was
measured with a miRNA-specific TaqMan assay on a
QuantStudio 12k Flex system, using TaqMan Fast Advanced
Master Mix (Life Technologies). The miRNA expression val-
ues were calculated according to the comparative threshold
cycle method (26), using ubiquitous and stably expressed let-
7a and RNU44 as endogenous controls. Let-7a was used to
normalize the expression of miRNAs in the real-time quantita-
tive polymerase chain reaction (qPCR) analysis performed in
the patient cohorts, while RNU44 was used to normalize data
in the in vitro experiments. The mean value of control samples
was set to 1, and the fold change in miR-618 expression in
patients or treated cells versus controls was calculated.
Expression of protein-coding genes was analyzed
by real-time qPCR using a 3-ng RNA equivalent after
retrotranscription with an iScript reverse transcriptase kit
(Bio-Rad). Reactions were conducted using SYBR Select
Master Mix with 500 nM specific primer pairs on a
QuantStudio 12k Flex system. Real-time qPCR data were nor-
malized to the expression of GUSB and analyzed as described
for miRNAs. A list of all primers and TaqMan probes used is
available upon request from the corresponding author.
Luciferase assay. Luciferase assays were performed
on 10,000 HT0180 cells transfected with 100 ng LightSwitch
30-UTR–specific or control reporter vectors in the presence
of 50 nM miR-618 mimic or a non-targeting scrambled
miRNA for 24 hours. Luciferase activity was measured on a
luminometer after the addition of LightSwitch Luciferase
Assay Reagent and expressed as the percentage of the lucifer-
ase signal observed with the miR-618 mimic compared to the
non-targeting control.
Luminex analysis. Measurement of soluble IFNa, IL-6,
tumor necrosis factor (TNF), and CXCL4 was performed on
cell-free supernatants diluted 1:50, using a multiplex immuno-
assay based on Luminex xMAP technology at the MultiPlex
Core Facility of the Laboratory of Translational Immunology,
University Medical Center Utrecht (27). Acquisition was per-
formed with a Bio-Rad FlexMap 3D system using xPonent
software version 4.2. Concentration values were calculated
using Bio-Plex Manager software version 6.1.1.
Statistical analysis. The nonparametric Mann-
Whitney and Kruskal-Wallis tests were applied to compare
2 groups or multiple groups, respectively, unless otherwise
stated. The correlation analysis was computed using Spearman’s
rho. All analyses were performed using GraphPad Prism 6.0
software. P values less than 0.05 were considered significant.
RESULTS
Up-regulation of miR-618 expression in PDCs
from SSc patients with overt cutaneous fibrosis. To
identify potential dysregulation of miRNA expression in
PDCs from patients with SSc, miRNA profiling was per-
formed in PDCs isolated from the peripheral blood of
patients with the most severe form of cutaneous fibrosis,
namely dcSSc, with a disease duration of #2 years
(n5 5) or .2 years (n5 7) (discovery cohort) (Table 1).
Of the 472 miRNAs measured, 42 miRNAs were differ-
entially expressed in the entire group of dcSSc patients
compared to healthy controls (Supplementary Table 1,
available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.40163/abstract).
Among these, 21 miRNAs were also significantly up-
regulated when patients with early dcSSc were considered as
a separate group (Supplementary Table 1).
Independent miRNA-specific analysis was per-
formed using a second unrelated cohort (the fibrotic
cohort) comprising SSc patients (n5 35) and healthy
controls (n5 23). Seven miRNAs ranked in the top
quartile were selected for replication (Figure 1A). This
analysis confirmed that miR-618 was consistently up-
regulated in PDCs from SSc patients compared to their
healthy counterparts (fold change 3.85; P, 0.0001), and
miR-618 expression was similar in lcSSc (fold change
versus healthy controls 3.37; P5 0.002) and dcSSc (fold
change versus healthy controls 4.87; P5 0.003) (Figures
1B and C). Of note, the majority of patients included in
the dcSSc group (7 of 10) had a disease duration of #2
years, and they showed higher miR-618 expression than
healthy controls. In addition, miR-618 expression levels
correlated well with the presence of the SSc-specific
complication ILD (fold change 2.37; P5 0.034) (Figure
1D) but not significantly with PAH (fold change 2.11;
P5 0.120) (Figure 1E). No correlation with other clini-
cal parameters was observed. The expression of the
other 5 miRNAs was not replicated (data available
upon request from the corresponding author), and
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hence only miR-618 was included in further functional
analysis.
Up-regulation of miR-618 expression in SSc
patients without cutaneous fibrosis. Since miR-618
expression was consistently up-regulated in dcSSc
patients at an early disease stage, we further examined
its levels in PDCs from subjects with nonfibrotic SSc
features in a third cohort comprising 35 patients and 11
healthy controls, i.e., the nonfibrotic cohort. This cohort
comprised patients with noncutaneous SSc and those
Figure 1. Up-regulation of microRNA-618 (miR-618) expression in plasmacytoid dendritic cells (PDCs) from patients with systemic sclerosis
(SSc). A, Heatmap showing the relative expression of 7 miRNAs that were significantly up-regulated in PDCs from patients with late diffuse
cutaneous SSc (ldcSSc; disease duration .2 years) and patients with early dcSSc (edcSSc; disease duration #2 years) compared to PDCs from
healthy controls (HC), out of a total of 470 miRNAs examined, in the discovery cohort. B and C, Expression of miR-618, measured by real-time
quantitative polymerase chain reaction, in PDCs from patients in the fibrotic cohort as a whole (B) and patients in the fibrotic cohort divided
into those with limited cutaneous SSc (lcSSc) and those with dcSSc (C). D and E, Expression of miR-618 in patients who did not have interstitial
lung disease (ILD) and those who did have ILD (D) and in patients who did not have pulmonary arterial hypertension (PAH) and those who
did have PAH (E). F and G, Expression of miR-618 in PDCs from patients in the nonfibrotic cohort as a whole (F) and patients in the non-
fibrotic cohort divided into those with early SSc (eaSSc) and those with noncutaneous SSc (ncSSc) (G). One healthy control was removed from
analysis after application of the robust regression and outlier removal method. H, Expression of miR-618 in whole blood samples from the same
donors as in G. I, Correlation of miR-618 levels in whole blood samples from patients in the nonfibrotic cohort with the European League
Against Rheumatism/American College of Rheumatology 2013 SSc classification score. Correlation was determined using Spearman’s rho. In B–
H, symbols represent individual subjects; horizontal lines show the geometric mean fold change (FC) in expression relative to healthy controls.
*5P, 0.05; **5P, 0.01; ****5P, 0.0001, by nonparametric Mann-Whitney test in B, D, E, and F and by Kruskal-Wallis test followed by
Dunn’s correction for multiple comparisons in C, G, and H.
MODULATION OF PDC DEVELOPMENT AND ACTIVATION BY miR-618 1895
with early SSc, who do not have skin involvement (Table
1). The expression of miR-618 was significantly higher
in nonfibrotic patients as a whole (fold change versus
healthy controls 1.56; P5 0.016) (Figure 1F), while it
showed a trend toward up-regulation when the 2 groups
were considered independently (Figure 1G). These
results demonstrate that miR-618 is up-regulated in SSc
from the earliest nonfibrotic stages of the disease. Simi-
lar to what was observed in PDCs, the expression of
miR-618 in the whole blood of the same patients
showed a similar trend and correlated well with the SSc
classification score (20) (Figures 1H and I). In contrast,
no variations in miR-618 levels were detected in
monocytes from any SSc patient groups, indicating that
miR-618 up-regulation could be cell specific (data avail-
able upon request from the corresponding author).
Targeting of multiple genes implicated in PDC
regulation and SSc pathogenesis by miR-618. To gain
insight into the biologic relevance of miR-618 up-regu-
lation in the PDCs of SSc patients, a list of ;2,500 genes
with high likelihood to be potential miR-618 targets
(data available upon request from the corresponding
author), with a prediction score of .0.8 according to
ComiR (http://www.benoslab.pitt.edu/comir) [28]), was
compared to a group of ;300 genes linked to SSc path-
ogenesis, SSc genetic susceptibility, PDC activation, and
Figure 2. Targeting of multiple genes important for plasmacytoid dendritic cell (PDC) biology and systemic sclerosis (SSc) pathogenesis by
microRNA-618 (miR-618). A, Venn diagram showing the overlap of miR-618 target genes as predicted by ComiR, according to the algorithms
miRanda, PITA, TargetScan, and mirSVR, and a list of relevant genes for SSc PDCs compiled on the basis of literature searches. B, Genes
selected from the intersection of the Venn diagram in A, listed according to the number of prediction algorithms identifying the interaction with
miR-618 and the ComiR prediction score. Shading indicates the top-ranking genes for each category, i.e., those with the highest ComiR scores
and predicted by all algorithms considered. C, Response of the 6 best-ranking genes in B to treatment with miR-618. The 30-untranslated regions
of the 6 best-ranking genes were cloned downstream of the Renilla luciferase gene and cotransfected into HT0180 cells with a miR-618 mimic or
a non-targeting miRNA control (scrambled miRNA [miR-Scr]). Luciferase assays were performed, and the response to miR-618 treatment was
expressed as relative luminescence units comparing miR-618 to the average of the scrambled miRNA–treated samples, set to 1. The miR-618
construct was used as a positive control carrying a sequence perfectly complementary to miR-618, while the GAPDH construct was used as nega-
tive control given that this gene does not contain any predicted binding site for miR-618. Bars show the mean6SD of 3 experiments.
*5P, 0.05; **5P, 0.01, by t-test.
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PDC differentiation (data available upon request from
the corresponding author) (1,9,15,19,29–33). This com-
parison led to the identification of 34 possible SSc- and
PDC-relevant miR-618 target candidates, of which 21
genes are expressed in the human immune system
(GeneCards; http://www.genecards.org/) (Figures 2A
and B). To experimentally verify whether these genes
are actively regulated by miR-618, we performed
Figure 3. MicroRNA-618 (miR-618) targets interferon regulatory factor 8 (IRF-8) in plasmacytoid dendritic cells (PDCs). A and C, Expression
of IRF-8 mRNA (A) and protein (C) in PDCs from healthy controls (HC; n5 12) and patients with systemic sclerosis (SSc; n5 18) in the
fibrotic cohort, analyzed by real-time quantitative polymerase chain reaction (qPCR). Symbols represent individual subjects; horizontal lines
show the geometric mean. B, Correlation of IRF-8 mRNA expression with miR-618 expression. Correlation was determined using Spearman’s
rho. D–L, Expression of miR-618 (D, G, and J), expression of IRF-8 (E, H, and K), and representative overlays of flow cytometric analysis (F, I,
and L) in PDCs from healthy donors (D–F), CAL-1 cells (G–I), and PDCs from SSc patients (J–L). Cells were transfected with miR-618 or
scrambled miRNA (miR-Scr), or with anti–miR-618 or anti–scrambled miRNA as indicated. After 24 hours, the expression of miR-618 was eval-
uated by real-time qPCR; anti–miR-618 is not expected to modify miR-618 expression. In parallel, a duplicate sample was stained intracellularly
with anti–IRF-8 antibody or an isotype control, and the expression of IRF-8 was analyzed by flow cytometry. The median mean fluorescence
intensity (MFI) of each sample was expressed relative to the nontransfected sample, set to 1. Gray and black histograms represent isotype and
IRF-8 staining, respectively. In D, G, and J, bars show the median and range. *5P, 0.05 by Mann-Whitney test in A, by t-test in C, and by t-
test for paired observations in E, H, and K. FC5 fold change.
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luciferase assays by cotransfecting a miR-618 mimic or a
scrambled miRNA control together with reporter con-
structs carrying the 30-UTRs of the 6 best-ranking genes.
When compared to scrambled miRNA–transfected
cells, the presence of miR-618 significantly inhibited the
luciferase activity of 5 of the 6 genes tested, thus demon-
strating that these genes, namely TP53INP1, IRF8,
IFNAR1, PTEN, and BCL2, contain a functional binding
site for miR-618 in their 30-UTR (Figure 2C). Overall,
these data show that miR-618 can regulate genes impli-
cated in PDC activation and differentiation, possibly
contributing to the dysregulation of these cells in SSc.
IRF-8 is an endogenous target of miR-618 in
PDCs. In order to identify the strongest miR-618 target
in the context of PDCs from SSc patients, the expression
of the 5 validated targets of miR-618 was analyzed in
Figure 4. Inhibition of plasmacytoid dendritic cell (PDC) development by up-regulation of microRNA-618 (miR-618). CD341 hematopoietic
progenitor cells were retrovirally transduced to generate stem cell precursors stably overexpressing miR-618 or a scrambled miRNA control
(miR-Scr), and cultured in vitro to obtain CD1231BDCA41 PDCs. A and B, Levels of miR-618 (A) and interferon regulatory factor 8 (IRF-8)
mRNA (B), measured by real-time quantitative polymerase chain reaction 3 days after transduction. Bars show the median and range. C and D,
Frequency of HLA–DR1 cells (C) and PDCs (D) on day 10 and day 13 of culture, determined by flow cytometric analysis using anti–HLA–DR,
anti-BDCA4, and anti-CD123 monoclonal antibodies. Plots show a representative experiment of 2 independently performed experiments with
similar results. Values are the percentage of cells. E and F, Percentage of PDCs circulating in the peripheral blood of healthy controls (HC) and
systemic sclerosis (SSc) patients as a whole (E) and in the peripheral blood of healthy controls and SSc patients divided into those with early
SSc (eaSSc), noncutaneous SSc (ncSSc), limited cutaneous SSc (lcSSc), and diffuse cutaneous SSc (dcSSc) (F). The percentage of PDCs was
determined by flow cytometric analysis after staining the peripheral blood mononuclear cell fraction using anti–HLA–DR, anti-CD123, and anti-
CD303 monoclonal antibodies. PDCs were decreased in the circulation of SSc patients. Symbols represent individual subjects; horizontal lines
show the median percentage of PDCs of total mononuclear cells. **5P, 0.01; ***5P, 0.001; ****5P, 0.0001, by Kruskal-Wallis test fol-
lowed by Dunn’s correction for multiple comparisons. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.
wiley.com/doi/10.1002/art.40163/abstract.
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PDCs isolated from SSc patients and healthy controls in
the fibrotic cohort. In PDCs from SSc patients, mRNA for
IRF-8 was significantly lower than in healthy controls (fold
change 0.4; P5 0.047) and was inversely correlated with
the expression of miR-618 (r520.478, P5 0.021) (Fig-
ures 3A and B). In contrast, the other genes tested were
not consistently modulated in SSc, and their expression
did not correlate with that of miR-618 (data available
upon request from the corresponding author). Consistent
with differences observed in IRF8 mRNA expression lev-
els, IRF-8 protein expression showed a trend toward
down-regulation in PDCs from SSc patients (Figure 3C).
To verify whether IRF-8 is an endogenous target of miR-
618 in PDCs, the miR-618 mimic was transfected into pri-
mary PDCs from healthy donors. The efficient overexpres-
sion of miR-618 in PDCs (Figure 3D) resulted in the
inhibition of IRF-8 protein expression compared to cells
transfected with a non-targeting miRNA (P5 0.044) (Fig-
ures 3E and F). Similar results were obtained by performing
the same experiment in the human PDC line CAL-1
(P5 0.023), confirming the ability of miR-618 to inhibit
IRF-8 expression in PDCs (Figures 3G–I). In contrast, inhi-
bition of miR-618 in PDCs isolated from SSc patients par-
tially normalized IRF-8 expression levels (Figures 3J–L).
Modulation of PDC development and activation
by the up-regulation of miR-618. IRF-8 governs the
differentiation of DC subsets and is essential for PDC
development (34). To determine whether miR-618
affects PDC differentiation by targeting IRF-8 activity,
we overexpressed miR-618 in an in vitro model of PDC
development (25). Consistent with the findings
described above, IRF-8 expression was lower when
miR-618 was overexpressed in this model (Figures 4A
and B). Furthermore, the number of HLA–DR1 cells
and BDCA41CD1231 PDCs generated from stem cell
precursors overexpressing miR-618 was reduced on
both day 10 and day 13 of culture (Figures 4C and D).
These experiments suggest that the inhibition of IRF-8
mediated by miR-618 is functional and does influence
the development of PDCs. Consistent with this finding,
we observed that the number of circulating PDCs was
significantly reduced in the peripheral blood of all SSc
patient groups except the early SSc group (Figures 4E
and F). These results suggest that the up-regulation of
miR-618 may contribute to the reduced presence of this
cell type in the circulation of SSc patients.
IRF-8 and other possible targets of miR-618 con-
stitute important molecular mediators of cytokine
release upon PDC stimulation (34). To examine this,
PDCs isolated from healthy individuals were transfected
with either miR-618 mimic or a non-targeting scrambled
miRNA control and activated in vitro with the synthetic
TLR-9 ligand type C CpG ODN dsDNA. Compared to
those transfected with mimic controls, PDCs over-
expressing miR-618 secreted higher levels of IFNa but
not IL-6, TNF, or CXCL4 (Figure 5A). The increased
release of IFNa observed upon miR-618 overexpression
did not occur via IRF-8 inhibition, since silencing of
IRF-8 in PDCs led to strong inhibition of IFNa produc-
tion (Supplementary Figure 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40163/abstract). Consistently, inhibition
of IRF-8 also blocked the release of IL-6 and TNF (Sup-
plementary Figure 1), while up-regulation of miR-618
did not affect these cytokines (Figure 5A).
The release of greater amounts of IFNa by
PDCs overexpressing miR-618 was concomitant with
Figure 5. Up-regulation of microRNA-618 (miR-618) enhances
interferon-a (IFNa) release by plasmacytoid dendritic cells (PDCs).
A, Release of IFNa, interleukin-6 (IL-6), tumor necrosis factor
(TNF), and CXCL4 by PDCs from healthy controls (HC) that were
transfected with miR-618 or scrambled miRNA (miR-Scr), rested
overnight, and stimulated for 24 hours with 1 mM type C CpG-
containing oligodeoxyribonucleotide (CpG ODN). Release was mea-
sured in cell-free supernatants using Luminex assays. B, Expression
of IFIT1 by RNA isolated from PDCs from healthy donors that were
transfected with miR-618 or scrambled miRNA, rested overnight,
and stimulated for 24 hours with 1 mM type C CpG ODN. Bars
show the geometric mean6 SEM of 8 experiments. C, Relative levels
of IFIT1 mRNA in PDCs isolated from healthy controls and sys-
temic sclerosis (SSc) patients in the fibrotic cohort. Symbols repre-
sent individual subjects; horizontal lines show the geometric mean.
*5P, 0.05 by nonparametric Wilcoxon test for paired samples in B
and by Mann-Whitney test in C. FC5 fold change.
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an increased expression of mRNA encoding IFIT1
(P5 0.042), an IFN-responsive gene (Figure 5B). Simi-
larly, we found that PDCs from SSc patients had higher
IFIT1 expression than those from healthy controls
(fold change 3.3; P5 0.03) (Figure 5C), consistent with
previous findings demonstrating the presence of a type
I IFN signature in the circulation and skin of SSc
patients (14,35). Consistent with these observations,
previous results by our group obtained using the same
culture conditions demonstrated that PDCs isolated
from SSc patients produce higher amounts of IFNa in
response to TLR-9 stimulation as compared to healthy
cells (13). Overall, these results demonstrate that the
up-regulation of miR-618 in PDCs can also influence
their activation in terms of IFNa release and may
therefore contribute to the type I IFN signature pres-
ent in SSc patients.
DISCUSSION
PDCs constitute a critical source of type I IFNs
that can contribute to the onset and perpetuation of
autoimmunity. However, the molecular mechanisms
that initiate and sustain dysregulation of PDCs are
largely unexplored, especially in SSc. Similar to what
has been observed in other autoimmune diseases char-
acterized by a type I IFN signature, such as SLE and
primary Sj€ogren’s syndrome (36–39), we show here that
PDCs are decreased in the circulation of SSc patients
and exhibit up-regulated expression of IFN-responsive
genes. Using miRNA expression profiling and validation
in multiple cohorts, we demonstrated that expression of
one miRNA, miR-618, is increased in the PDCs of SSc
patients and mediates regulatory mechanisms that may
contribute to the derailment of PDCs in this disease.
According to prediction analysis and reporter assays,
miR-618 targets genes involved in PDC differentiation/
activation or previously associated with SSc pathogene-
sis. Among those tested, IRF-8 was validated as the
strongest miR-618 target, as its expression was inversely
correlated with miR-618 levels in SSc PDCs and
inhibited upon ectopic overexpression of miR-618.
Underlying the importance of IRF-8 targeting by
miR-618 is the fact that 3 distinct polymorphisms associ-
ated with SSc susceptibility are located downstream of
the genomic region encoding for IRF-8 (40–42). How-
ever, we have verified that the action of miR-618 on
IRF-8 expression is independent of the presence of any
SSc risk allele within the IFR8 genomic region, since
none of the previously identified SSc-associated single-
nucleotide polymorphisms or their proxies were located
inside the binding sites of miR-618 or within the 30-
UTR of IRF-8 (data available upon request from the
corresponding author). That both genetic and epige-
netic factors independently contribute to IRF-8 dysreg-
ulation underscores the importance of this IFN-
responsive transcription factor in the pathogenic pro-
cesses underlying SSc development.
IRF-8 is a crucial transcription factor in both PDC
development and PDC activation (34). IRF-8–deficient
mice show profound defects in the DC compartment,
since they lack both CD11c1CD8a1 DCs and PDCs
(43–47). In humans, mutations in IRF-8 lead to either a
total absence of or a strong decrease in circulating DCs,
resulting in severe immunodeficiency in the affected
patients (48). Consistent with the capacity of miR-618 to
suppress IRF-8 expression, miR-618 also reduces the
development of PDCs from CD341 cells. Along with the
migration of PDCs into the affected tissues previously
demonstrated in SSc (13), the up-regulation of miR-618
may therefore favor the decrease in circulating PDCs
observed in SSc patients.
Besides its role in cell differentiation, IRF-8 is
activated upon TLR stimulation and, in association with
other transcription factors, activates or represses the
expression of specific genes including numerous cyto-
kines and costimulatory molecules (34). Macrophages
and DCs from IRF-8–deficient mice remain immature
and have impaired responses to TLR activation. How-
ever, the role of IRF-8 in PDC activation is still a subject
of controversy (49), as IRF-8 was reported to inhibit
cytokine release upon TLR-9 stimulation in the human
PDC line CAL-1 (50), while it has also been shown to
favor type I IFN release by murine PDCs (51). This is
the first study to demonstrate that the silencing of IRF-
8 impairs the activation of primary human PDCs,
resulting in decreased IFNa secretion by PDCs. There-
fore, the higher release of soluble IFNa observed upon
miR-618 overexpression in primary human PDCs is
likely mediated by additional miR-618 targets other
than IRF-8. It is possible that the up-regulated expres-
sion of miR-618 in PDCs from SSc patients also results
in increased IFNa release in vivo, thus contributing to
the establishment of the type I IFN signature observed in
SSc patients (14,35,52). This hypothesis would be consis-
tent with our previous finding that PDCs isolated from
SSc patients produce a greater amount of IFNa in
response to TLR-9 stimulation than healthy cells (13). In
contrast, we did not observe any relevant impact of miR-
618 expression on the release of CXCL4, the cytokine
abundantly released by PDCs from SSc patients (13).
Whether the immune system plays a primary
role in SSc initiation and/or disease maintenance
remains an open question. However, increasing
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evidence demonstrates that autoimmunity is not a mere
consequence of tissue damage, but also is a prominent
factor that can contribute to SSc pathogenesis.
Supporting this concept, we recently demonstrated that
the type I IFN signature in blood monocytes from SSc
patients is present not only in patients with established
SSc but also in patients with early SSc without any signs
of fibrosis (14). Similarly, in this study we show that
miR-618 is incrementally up-regulated in patients with
early SSc (fold change versus healthy controls 1.35), in
SSc patients without fibrosis (fold change 1.41), and in
subjects with overt fibrosis (fold change 3.85), including
those with dcSSc with a disease duration of #2 years
(fold change 3.68). Considering that these patients could
progress to a more severe phenotype and develop cuta-
neous and/or internal organ fibrosis over time, the up-
regulation of miR-618 expression may represent one of
the multiple molecular aberrances occurring during SSc
evolution. Consistently, higher levels of miR-618 are
associated with the presence of ILD, a severe clinical
complication resulting from the development of visceral
fibrosis (53).
Consistent with the recent demonstrations of a
notable role of PDCs in the development of systemic auto-
immunity in mouse models of SLE (6–8), the data pres-
ented here support the concept that molecular aberrances
occurring early in the PDCs of patients with SSc could
impact the entire immune system, thus inducing autoim-
munity and ultimately favoring the onset of SSc and its
progression. While in vivo studies are necessary to prove
the role of miR-618 in SSc development, this miRNA may
represent a potential novel epigenetic target for restoring
immune system homeostasis in SSc and in other diseases
characterized by a type I IFN signature.
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